Avalign And Subsidiary Instrumed To Pay $9.5M In Uncleared Device Settlement
Executive Summary
Avalign Technologies is paying $9.5m to settle fraud charges. The company and its Instrumed International subsidiary sold unapproved devices that they falsely claimed held pre-amendment status.
You may also be interested in...
FCA 2019: Key Issues Include DOJ Dismissal, Statute Of Limitations
Court rulings related to the False Claims Act (FCA) this year focused on whistleblower rules and further clarifying the theory of liability, given in the Supreme Court’s 2016 Escobar decision, Gibson Dunn health-care attorneys say.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
FDA Leader Looks To International Effort On Pediatric Device Development
Collaboration with Japan and Europe could help ease the development path for pediatric devices, cardiovascular device office director Bram Zuckerman said at a recent conference. Zuckerman also spoke on other cardiac device priorities at the FDA.